Placebo (SD) | Sildenafil (SD) | p-value | |
---|---|---|---|
n = 10 | n = 10 | ||
Age (years) | 72 (9) | 63 (9) | 0.09 |
Female (%) | 50 | 30 | 0.51 |
Height (cm) | 170 (10) | 171 (7) | 0.87 |
Weight (kg) | 87 (13) | 86 (10) | 0.83 |
BMI (kg/m2) | 30 (3) | 30 (4) | 0.77 |
Known active cancer (%) | 0 | 0 | 1.00 |
Immobilisation (%) | 10 | 20 | 0.59 |
Recent surgery/trauma (%) | 10 | 20 | 0.59 |
Previous VTE (%) | 50 | 10 | 0.04 |
COPD (%) | 0 | 20 | 0.17 |
DM (%) | 30 | 10 | 0.17 |
Smoking (%) | 10 | 10 | 1.00 |
Estrogen (%) | 10 | 10 | 1.00 |
Duration of symptoms (d) | 3.0 (1.3) | 2.7 (1.3) | 0.66 |
UFH/LMH/VKA/NOAK (n) | 2/7/0/1 | 0/9/0/1 | na |
Oxygen therapy (l) | 1.8 (1.4) | 1.9 (1.9) | 0.85 |
TnT (ng/l) | 198 (131) | 136 (150) | 0.66 |
NT proBNP (ng/l) | 6573 (8624) | 1201 (113) | 0.08 |
RF (/min) | 18 (3) | 19 (3) | 0.19 |
Periferal saturation (%) | 96 (2) | 95 (2) | 0.13 |
Pulse (BPM) | 70 (9) | 85 (12) | 0.02 |
BPs (mmHg) | 134 (10) | 137 (24) | 0.55 |
BPd (mmHg) | 81 (9) | 88 (12) | 0.25 |
RV diameter* (cm) | 5.4 (0.5) | 5.2 (0.8) | 0.70 |
LV diameter* (cm) | 3.7 (0.5) | 3.2 (0.5) | 0.06 |
RV/LV* | 1.5 (0.3) | 1.7 (0.5) | 0.23 |